Philip J Mease

Philip J Mease

UNVERIFIED PROFILE

Are you Philip J Mease?   Register this Author

Register author
Philip J Mease

Philip J Mease

Publications by authors named "Philip J Mease"

Are you Philip J Mease?   Register this Author

100Publications

4109Reads

42Profile Views

Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap.

Rheumatol Ther 2019 Dec 31;6(4):487-501. Epub 2019 Oct 31.

Swedish Medical Center and University of Washington, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40744-019-00176-5DOI Listing
December 2019

Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018.

J Rheumatol 2019 Oct 1;46(10):1355-1359. Epub 2019 Apr 1.

From the Department of Epidemiology and Biostatistics, Amsterdam University Medical Centre (VUmc); VUmc, Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam; Department of General Practice, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands; Comprehensive Pain Center, University Hospital Carl Gustav Carus Dresden, Medical Faculty of the Technical University Dresden, Dresden, Germany; CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University, Cardiff; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds; Versus Arthritis, Patron Her Royal Highness The Duchess of Cornwall, Chesterfield; MRC North West Hub for Trials Methodology Research, Department of Biostatistics, University of Liverpool, Liverpool, UK; Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen; The Rheumatology Research Unit, Department of Rheumatology, Odense University Hospital; Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark; Dragon Claw (Website for patients with rheumatic disease), New South Wales, Australia; Bingo and Fundraising Promotions, Mal Atwell Leisure Group, Willetton, Australia; SDG LLC, Cambridge, Massachusetts; Medicine Service, VA Medical Center; Departments of Medicine and Epidemiology at the Schools of Medicine and Public Health, University of Alabama at Birmingham, Birmingham, Alabama; Department of Anesthesiology and Pain Medicine, University of Washington; Rheumatology Research Swedish-Providence-St. Joseph Health Systems; University of Washington School of Medicine, Seattle, Washington, USA; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.181099DOI Listing
October 2019

Revised chronic widespread pain criteria: development from and integration with fibromyalgia criteria.

Scand J Pain 2019 Oct 9. Epub 2019 Oct 9.

National Institute of Nursing Research, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/sjpain-2019-0054DOI Listing
October 2019

Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients.

J Rheumatol 2019 Oct 15. Epub 2019 Oct 15.

From the Johns Hopkins University School of Medicine, Baltimore, MD, USA; University of Glasgow, Glasgow, United Kingdom; University of Oxford, Oxford, United Kingdom; Cleveland Clinic, Cleveland, OH, USA; Toronto Western Research Institute and University of Toronto, Toronto, ON, Canada; Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France; Pitié Salpêtrière Hospital, AP-HP, Paris, France; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA. This study is funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ. Support for third-party writing assistance for this manuscript, furnished by Eric Deutsch, PhD, CMPP, of Health Interactions, Inc, was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Conflicts of Interest: A-M. Orbai has received grant support from AbbVie, Celgene, Horizon, Janssen, Lilly, and Novartis, consulting fees from Janssen, Lilly, Novartis, Pfizer, and UCB, is a Jerome L Greene Foundation Scholar and is supported in part by a research grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Secukinumab Improves GRAPPA-OMERACT Domains Institutes of Health (NIH) under award number P30- AR070254 (Core B), a Rheumatology Research Foundation Scientist Development Award, and a Staurulakis Family Discovery Award. I. B. McInnes has received grant support from Bristol-Myers Squibb, Celgene, Janssen, and UCB, and consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Leo, Lilly, Novartis, Pfizer, and UCB. L. C. Coates has received grant support from AbbVie, Celgene, Novartis, and Pfizer, consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Galapagos, Gilead, Janssen, Lilly, MSD, Novartis, Pfizer, Prothena, Sun Pharma, and UCB, and speakers bureau fees from AbbVie, Celgene, Janssen, Lilly, Novartis, and UCB. M. E. Husni has received grant support from Janssen. D. D. Gladman has received grant support from AbbVie, Amgen, Celgene, Lilly, Novartis, Pfizer, and UCB, and consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. L. Gossec has received grant support from Bristol-Myers Squibb, Lilly, Pfizer, and UCB, and consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Pfizer, Roche, and UCB. L. Pricop, O. Chambenoit, and X. Meng are employees and stockholders of Novartis. P. J. Mease has received research grants from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun Pharma, and UCB; consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun Pharma, and UCB; and speakers bureau fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer, and UCB. A.-M. Orbai, MD, MHS, Johns Hopkins University School of Medicine, Baltimore, MD, USA; I. B. McInnes, MD, PhD, University of Glasgow, Glasgow, United Kingdom; L. C. Coates, MBChB, PhD, University of Oxford, Oxford, United Kingdom; M. E. Husni, MD, MPH, Cleveland Clinic, Cleveland, OH, USA; D. D. Gladman, MD, FRCPC, Toronto Western Research Institute and University of Toronto, Toronto, ON, Canada; L. Gossec, MD, PhD, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France, and Pitié Salpêtrière Hospital, Secukinumab Improves GRAPPA-OMERACT Domains AP-HP, Paris, France; L. Pricop, MD, O. Chambenoit, PhD, X. Meng, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; P. J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA. Address correspondence and requests for reprints to: Ana-Maria Orbai, MD, MHS (ORCID iD: 0000-0001-8644-8567), Assistant Professor of Medicine, Johns Hopkins University School of Medicine, Division of Rheumatology, MFL Center Tower, Suite 4100, 5200 Eastern Ave, Baltimore, MD 21224; Tel: 410-550-8231; Fax: 410-550-2072; Email:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.190507DOI Listing
October 2019

Measurement properties of the minimal disease activity criteria for psoriatic arthritis.

RMD Open 2019 6;5(2):e001002. Epub 2019 Sep 6.

School of Medicine, Swedish Medical Center and University of Washington, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2019-001002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744081PMC
September 2019

PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.

J Rheumatol 2019 Aug 15;46(8):990-995. Epub 2018 Dec 15.

From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore; Department of Medicine, Duke University School of Medicine, Durham, North Carolina; Kezar Life Sciences, South San Francisco; Division of Immunology, Stanford University, Palo Alto, California; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Global Patient Outcomes and Real World Evidence, Eli Lilly and Co., Indianapolis, Indiana; University of Pennsylvania, Philadelphia, Pennsylvania; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; Royal Prince Alfred Hospital Medical Centre, Sydney, Australia; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Royal National Hospital for Rheumatic Diseases, Bath; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Musculoskeletal Statistics Unit: The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen; Department of Rheumatology, Odense University Hospital, Odense, Denmark; Sorbonne Université; Rheumatology Department, Pitié Salpêtrière Hospital, AP-HP, Paris, France; VU Medical Centre, Amsterdam, the Netherlands; Global Medical Affairs, Pfizer Inc., Montreal, Quebec; Clinical Epidemiology Program, Ottawa Hospital Research Institute; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital and Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute, Institute for Health Policy Management and Evaluation, University of Toronto; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada; Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.181077DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6571063PMC
August 2019

The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set.

J Rheumatol Suppl 2019 Jun;95:33-37

From the Duke-NUS Medical School, Singapore; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Dermatology, University of Utah, Salt Lake City, Utah; Kezar Life Sciences, San Francisco; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford; Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; Amsterdam University Medical Centre, Department of Medical Humanities, Amsterdam, the Netherlands; Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.190122DOI Listing
June 2019

GRAPPA 2018 Project Report.

J Rheumatol Suppl 2019 Jun;95:54-57

From Kezar Life Sciences, San Francisco, California; Duke University School of Medicine, Durham, North Carolina, USA; Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; University of Toronto; Krembil Research Institute, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; UK National Institute for Health Research (NIHR), Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK; University of California at San Diego, La Jolla, California, USA; University of Alberta, Edmonton, Alberta, Canada; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington, USA; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.190121DOI Listing
June 2019

Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor.

J Rheumatol 2019 May 15;46(5):475-482. Epub 2019 Jan 15.

From the University of Pennsylvania, Philadelphia, Pennsylvania; Corrona Research Foundation; New York University Hospital for Joint Diseases, New York, New York; University of Alabama at Birmingham, Birmingham, Alabama; University of Massachusetts, Worcester; Brigham and Women's Hospital, Boston, Massachusetts; University of California San Diego, San Diego, California; Albany Medical College, Albany, New York; Swedish Medical Center; University of Washington, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://www.jrheum.org/lookup/doi/10.3899/jrheum.171034
Publisher Site
http://dx.doi.org/10.3899/jrheum.171034DOI Listing
May 2019

Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.

Arthritis Res Ther 2019 May 10;21(1):118. Epub 2019 May 10.

Rheumatology Clinical Research Division, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-019-1901-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509758PMC
May 2019

Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the US-Based Corrona Registry.

Arthritis Care Res (Hoboken) 2018 11 8;70(11):1661-1670. Epub 2018 Oct 8.

Corrona, LLC, Southborough, Massachusetts and New York University School of Medicine, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.23534DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282817PMC
November 2018

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

J Rheumatol 2018 10 1;45(10):1389-1396. Epub 2018 Jul 1.

From the Swedish Medical Center and University of Washington, Seattle, Washington; Novartis Pharmaceuticals Corp., East Hanover, New Jersey; Corrona LLC, Waltham, Massachusetts; University of California San Diego, La Jolla, California; Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center, Rochester; New York University School of Medicine, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.171094DOI Listing
October 2018

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis.

J Am Acad Dermatol 2018 Sep 17;79(3):593-595. Epub 2018 Mar 17.

Department of Rheumatology Research, Swedish-Providence-St. Joseph Health Systems and University of Washington School of Medicine, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.03.008DOI Listing
September 2018

Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study.

Arthritis Care Res (Hoboken) 2018 08 29;70(8):1206-1217. Epub 2018 May 29.

Parker Institute, Copenhagen University Hospital, and Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.23455DOI Listing
August 2018

Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study.

J Rheumatol 2018 08 15;45(9):1256-1262. Epub 2018 Jun 15.

From the Department of Medical Sciences, Policlinico of the University of Cagliari; Rheumatology Unit, and Department of Public Health, University of Cagliari, Cagliari; Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Matera; Rheumatology Research Unit, Department of Clinical and Experimental Medicine, University "Federico II," Naples; Department of Rheumatology, ASST Gaetano Pini-Centro Traumatologico Ortopedico (CTO), Milan; Rheumatology Unit, Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Modena and Reggio Emilia; Dipartimento di Medicina e Scienze della Salute, Università degli Studi del Molise, Campobasso, Italy; University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada; Academic Medical Center/University of Amsterdam; Amsterdam Rheumatology and Immunology Center Reade, Amsterdam, the Netherlands; Rehabilitation Teaching and Research Unit, Department of Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand; Medizinische Klinik III mit Poliklinik, Friedrich-Alexander-Universität Erlangen-Nuernberg, Erlangen, Germany; Sector of Dermatology, HUCFF School of Medicine, Federal University of Rio de Janeiro and Sector of Dermatology, HUPE School of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro, Brazil; Spondyloarthritis Program, Johns Hopkins University, School of Medicine, Baltimore, Maryland; Swedish Medical Centre and University of Washington School of Medicine, Seattle, Washington, USA; Department of Rheumatology, Semmelweis University, Budapest, Hungary; Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.171183DOI Listing
August 2018

Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study.

Ann Rheum Dis 2018 07 3;77(7):1091-1093. Epub 2017 Jul 3.

Department of Rheumatology, University Pierre et Marie Curie Paris 6 HÃ'pital Cochin, AP-HP, INSERM U1153 and PRES Sorbonne Paris City, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2017-211313DOI Listing
July 2018

Considerations for the definition of remission criteria in psoriatic arthritis.

Semin Arthritis Rheum 2018 06 31;47(6):786-796. Epub 2017 Oct 31.

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2017.10.021DOI Listing
June 2018

Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.

J Rheumatol Suppl 2018 Jun;94:17-25

From the Royal Prince Alfred Hospital Medical Centre, Sydney, Australia; Royal National Hospital for Rheumatic Diseases, Bath, UK; University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; University of Toronto, Krembil Research Institute, Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; University of Oxford, Oxford, UK; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada; Division of Immunology/Rheumatology, Stanford University, Palo Alto, California, USA; Department of Rheumatology, St. Vincents University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; VU Medical Centre, Amsterdam, the Netherlands; IQVIA, Duke University School of Medicine, Durham, North Carolina, USA; School of Epidemiology, Public Health, and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Ontario, Canada; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute, and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180142DOI Listing
June 2018

The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database.

J Rheumatol Suppl 2018 Jun;94:26-29

From the University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Orthopedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford; Department of Rheumatology, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge; Royal National Hospital for Rheumatic Diseases; University of Bath, Bath, UK; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; Department of Rheumatology, Erasmus Medical Center, Rotterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180132DOI Listing
June 2018

GRAPPA 2017 Project Report.

J Rheumatol Suppl 2018 Jun;94:48-51

From the University of Utah, Salt Lake City, Utah; University of California at San Diego, La Jolla, California; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology and Medicine, Division of Rheumatology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; New York University School of Medicine, New York; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital; Conway Institute for Biomolecular Research, University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180139DOI Listing
June 2018

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies.

Ann Rheum Dis 2018 05 26;77(5):e23. Epub 2017 Jul 26.

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2017-212004DOI Listing
May 2018

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).

J Rheumatol 2018 03 15;45(3):367-377. Epub 2017 Dec 15.

From the Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Immuno-Rheumatology Center, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan; Eli Lilly and Company, Indianapolis, Indiana, USA; Laboratoires Lilly France, Neuilly, France; Department of Rheumatology, Swedish Medical Center; University of Washington, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.170429DOI Listing
March 2018

CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study.

J Rheumatol 2018 01 1;45(1):22-31. Epub 2017 Nov 1.

From the Swedish Medical Center and University of Washington, Seattle, Washington; Janssen Research and Development LLC, Spring House, Pennsylvania, USA; Department of Rheumatology and Connective Tissue Diseases, 2nd University Hospital, CM UMK, Bydgoszcz, Poland; Centro de Reumatologia y Ortopedia, Universidad Metropolitana, Barranquilla, Colombia; Rajavithi Hospital, Bangkok, Thailand; Division of Rheumatology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand; Institute of Rheumatology, Prague, Czech Republic; Clinical Rheumatology Hospital #25, St. Petersburg, Russia; Head Rheumatology Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Janssen (China) Research and Development Center, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.161238DOI Listing
January 2018

Real-world burden of comorbidities in US patients with psoriatic arthritis.

RMD Open 2017 28;3(2):e000588. Epub 2017 Dec 28.

Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2017-000588DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761305PMC
December 2017

Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016.

J Rheumatol 2017 Oct 1;44(10):1522-1528. Epub 2017 Feb 1.

From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey.

View Article

Download full-text PDF

Source
http://www.jrheum.org/lookup/doi/10.3899/jrheum.160904
Publisher Site
http://dx.doi.org/10.3899/jrheum.160904DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538953PMC
October 2017

Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry.

J Rheumatol 2017 08 15;44(8):1151-1158. Epub 2017 Jun 15.

From the Swedish Medical Center and University of Washington (UW) Medicine, Seattle, Washington; Corrona LLC, Southborough, Massachusetts; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; The University of Texas MD Anderson Cancer Center, Houston, Texas; University of California (UC) at San Diego, La Jolla, California; University of Rochester Medical Center, Rochester; New York University (NYU) School of Medicine, New York, New York; Scott and White Health Plan, Temple, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.160963DOI Listing
August 2017

Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment.

Authors:
Philip J Mease

Curr Opin Rheumatol 2017 07;29(4):304-310

Rheumatology Clinical Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000388DOI Listing
July 2017

Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab.

J Rheumatol 2017 05 15;44(5):599-608. Epub 2017 Mar 15.

From Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine, Seattle, Washington; Department of Medicine, University of Illinois at Chicago; Immunology Clinical Development, AbbVie Inc., Chicago, Illinois, USA; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.160387DOI Listing
May 2017

Proceedings of the GRAPPA 2016 Retreat.

J Rheumatol 2017 05;44(5):668-673

From the Rheumatology Research Unit, Cambridge University Hospitals UK National Health Service (NHS) Foundation Trust, Cambridge; UK National Institute for Health Research Clinical Lecturer, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Bradford Hospitals NHS Foundation Trust, Bradford, UK; Department of Medicine, Division of Rheumatology, University of Toronto, Toronto Western Hospital, Krembil Research Institute; Division of Dermatology, Toronto Western Hospital, University of Toronto, Ontario; University of Alberta, Edmonton, Alberta, Canada; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Advisory Services, QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester; New York Medical College, Valhalla; Hofstra Northwell School of Medicine, New Hyde Park, New York, New York; Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Cleveland Clinic, Cleveland, Ohio; University of Utah, Salt Lake City, Utah; University of Southern California, Los Angeles; University of California at San Diego, San Diego, California, USA; Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Division of Rheumatology, University of Cagliari, Cagliari, Italy, Sección Reumatología, Servicio de Clínica Médica, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Federal University of Paraná, Curitiba, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.170141DOI Listing
May 2017

International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting.

J Rheumatol 2017 05;44(5):684-685

From the UK National Institute for Health Research (NIHR), Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; PsAZZ Support Group, Bath, UK; Department of Medicine, Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada; Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Cleveland Clinic, Cleveland, Ohio; Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York; University of California at San Diego, San Diego, California, USA; Our Lady's Hospice and Care Services, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.170144DOI Listing
May 2017

Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group.

J Rheumatol 2017 05;44(5):697-700

From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.170150DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605807PMC
May 2017

GRAPPA 2016 Project Report.

J Rheumatol 2017 05;44(5):706-710

From the UK National Institute for Health Research (NIHR); Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK; Department of Rheumatology, St. Vincent's University Hospital; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; University of Utah, Salt Lake City, Utah; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.170153DOI Listing
May 2017

Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry.

J Rheumatol 2017 02 15;44(2):184-192. Epub 2017 Jan 15.

From the Swedish Medical Center and University of Washington, Seattle, Washington; Amgen Inc., Thousand Oaks, California; Corrona LLC, Southborough, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.160343DOI Listing
February 2017

Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.

Nat Rev Rheumatol 2016 Dec 10;12(12):743-750. Epub 2016 Nov 10.

Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; and at the 2nd Department of Medicine, Hietzing Hospital, Wolkersbergenstraße 1, 1130 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrrheum.2016.183DOI Listing
December 2016

2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria.

Semin Arthritis Rheum 2016 12 30;46(3):319-329. Epub 2016 Aug 30.

National Institute of Nursing Research, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2016.08.012DOI Listing
December 2016

Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study.

J Rheumatol 2016 09 15;43(9):1713-7. Epub 2016 Jun 15.

From the University of California-San Diego, School of Medicine, LaJolla, California, USA; Immunology, Infection and Inflammation, University of Glasgow, Glasgow, UK; Swedish Medical Centre, and University of Washington School of Medicine, Seattle, Washington, USA; Monash University, Melbourne, Australia; UK National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals National Health Service NHS Foundation Trust, University of Manchester, UK; Altoona Center for Clinical Research, Duncansville, Pennsylvania; Novartis Pharmaceuticals Corp., East Hanover, New Jersey, USA; Novartis Pharma AG, Basel, Switzerland.A. Kavanaugh, MD, Professor of Clinical Medicine, Director of Center for Innovative Therapy, University of California-San Diego, School of Medicine; I.B. McInnes, MD, PhD, Professor of Experimental Medicine (Immunology), Muirhead Chair of Medicine and Director of Institute (School of Medicine), Immunology, Infection and Inflammation, University of Glasgow; P.J. Mease, MD, Clinical Professor, University of Washington School of Medicine, Director of the Rheumatology Clinical Research Division of Swedish Medical Center; S. Hall, MBBS, Professor, Director-Emeritus Research, Monash University; H. Chinoy, PhD, Senior Lecturer, Rheumatology, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, University of Manchester; A.J. Kivitz, MD, CPI, President, Altoona Center for Clinical Research; Z. Wang, PhD, Associate Director, Biometrician, Novartis; S. Mpofu, MD, Senior Global Program Medical Director, Novartis.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.160275DOI Listing
September 2016

Comparison of Physician-Based and Patient-Based Criteria for the Diagnosis of Fibromyalgia.

Arthritis Care Res (Hoboken) 2016 05;68(5):652-9

National Institute of Nursing Research, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.22742DOI Listing
May 2016

Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting.

J Rheumatol 2016 05;43(5):965-9

From the Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; VU Medical Centre, Amsterdam, The Netherlands, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA; Department of Internal Medicine, Division of Rheumatology, Hacettepe University Ankara, Ankara, Turkey; Toronto Western Hospital, Toronto, Ontario, Canada; Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; University of Toronto, Krembil Research Institute, Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada; Quintiles, Duke University School of Medicine, Durham, North Carolina, USA; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Cleveland Clinic, Cleveland, Ohio, USA; University of Leeds, Leeds, UK, and Bradford Hospitals National Health Service (NHS) Foundation Trust, Bradford, UK; Division of Immunology, Stanford University, Palo Alto, California, USA; University of Pennsylvania, Philadelphia, Pennsylvania, USA.A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; U. Kalyoncu, MD, Division of Rheumatology, Johns Hopkins University and Department of Internal Medicine, Division of Rheumatology, Hacettepe University Ankara; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; W. Tillett, BSc, MB, ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; L. Eder, MD, PhD, Toronto We

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.160116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5235387PMC
May 2016

GRAPPA 2015 Research and Education Project Reports.

J Rheumatol 2016 05;43(5):979-85

From the Swedish Medical Center, and the University of Washington School of Medicine, Seattle, Washington, USA; University of Leeds, Leeds; Bradford Hospitals National Health Service (NHS) Foundation Trust, Bradford, UK; Geneva University Hospital, Geneva, Switzerland; Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; University of Toronto and Krembil Research Institute, Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada; Rheumatology and Immunology, Oregon Health and Science University, Portland, Oregon; University of Utah, Salt Lake City, Utah, USA.P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; P.S. Helliwell, DM, PhD, FRCP, Senior Lecturer in Rheumatology, University of Leeds, and Bradford Hospitals NHS Foundation Trust; W.H. Boehncke, MD, Geneva University Hospital; L.C. Coates, MBChB, PhD, UK National Institute for Health Research Clinical Lecturer, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; A.A. Deodhar, MD, MRCP, FACP, FACR, Medical Director, Rheumatology and Immunology, Oregon Health and Science University; K. Callis Duffin, MD, University of Utah.

View Article

Download full-text PDF

Source
http://www.jrheum.org/cgi/doi/10.3899/jrheum.160119
Publisher Site
http://dx.doi.org/10.3899/jrheum.160119DOI Listing
May 2016

Presidential Round Table: A Report from the GRAPPA Annual Meeting.

J Rheumatol 2016 05;43(5):986-9

From the University of Toronto, and the Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; Department of Dermatology, Division of Specialties in Medicine, University of Geneva, Geneva, Switzerland; University of Leeds, Leeds; Bradford Hospitals National Health Service (NHS) Foundation Trust, Bradford, UK; University of Utah, Salt Lake City, Utah, USA.D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, Toronto Western Hospital; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine; W.H. Boehncke, MD, MA, Professor and Chair, Department of Dermatology, Division of Specialties in Medicine, University of Geneva; P.S. Helliwell, DM, PhD, FRCP, University of Leeds, Leeds, and Bradford Hospitals NHS Foundation Trust; K. Callis Duffin, MD, University of Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.160120DOI Listing
May 2016

Ms. A.M. Taylor, et al reply.

J Rheumatol 2016 Apr;43(4):826

Swedish Medical Center and University of Washington, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.151456DOI Listing
April 2016

Do Biologic-treated Psoriatic Arthritis Patients with Spondylitis Respond Differently with or without Concomitant Methotrexate from Patients without Spondylitis?

Authors:
Philip J Mease

J Rheumatol 2016 Mar;43(3):471-3

Swedish Medical Center, Division of Rheumatology Research; University of Washington School of Medicine, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.160046DOI Listing
March 2016

Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis.

J Rheumatol 2016 Feb 15;43(2):343-9. Epub 2016 Jan 15.

From the Swedish Medical Center; University of Washington, Seattle, Washington; Stanford University, Stanford; Amgen Inc., Thousand Oaks, California, USA.P.J. Mease, MD, Swedish Medical Center and University of Washington; M.C. Genovese, MD, Stanford University; A. Mutebi, PhD, Amgen Inc.; H.N. Viswanathan, PhD, Amgen Inc.; D. Chau, PharmD, Amgen Inc.; J. Feng, MS, formerly with Amgen Inc.; A. Nirula, MD, PhD, formerly with Amgen Inc.; N. Erondu, PhD, formerly with Amgen Inc.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.150182DOI Listing
February 2016

Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.

J Rheumatol 2016 Jan 1;43(1):81-7. Epub 2015 Dec 1.

From the Department of Rheumatology, and Musculoskeletal Statistics Unit, the Parker Institute, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, Sahlgrenska University, Gothenburg; Department of Rheumatology, Lund University Hospital, Lund, Sweden; Copenhagen University Hospital at Frederiksberg, Frederiksberg, Denmark.L.E. Kristensen, MD, PhD, Department of Rheumatology, the Parker Institute, and Department of Rheumatology, Lund University Hospital; E. Lie, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; L.T. Jacobsson, MD, PhD, Department of Rheumatology, Sahlgrenska University; R. Christensen, MD, PhD, Copenhagen University Hospital at Frederiksberg, and Musculoskeletal Statistics Unit, the Parker Institute; P.J. Mease, MD, PhD, Department of Rheumatology, Swedish Medical Center; H. Bliddal, MD, PhD, Copenhagen University Hospital at Frederiksberg, and Musculoskeletal Statistics Unit, the Parker Institute; P. Geborek, MD, PhD, Department of Rheumatology, Lund University Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.150744DOI Listing
January 2016

Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry.

RMD Open 2015 30;1(1):e000181. Epub 2015 Dec 30.

Epidemiology and Outcomes Research, Corrona, LLC, Southborough, Massachusetts, USA; Division of Rheumatology, New York University School of Medicine, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2015-000181DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716450PMC
January 2016

Validation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) for the Hand and Foot in a Randomized Placebo-controlled Trial.

J Rheumatol 2015 Dec 1;42(12):2473-9. Epub 2015 Nov 1.

From the Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet-Glostrup, University of Copenhagen; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; University of NSW, Sydney, Australia; Pitié Salpêtrière Hospital, APHP, Université Paris 6-UPMC, Paris, France; Swedish Medical Center and University of Washington, Seattle, Washington, USA; Diakonhjemmet Hospital, Oslo, Norway; Spire Sciences Inc., Boca Raton, Florida, USA; and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK.D. Glinatsi, MD, Research Fellow, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet-Glostrup, University of Copenhagen; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip MRI, Associate Professor, University of NSW; F. Gandjbakhch, MD, Practicing Rheumatologist, Department of Rheumatology, Pitié Salpêtrière Hospital, APHP, Université Paris 6-UPMC; P.J. Mease, MD, Swedish Medical Center and University of Washington; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; C.G. Peterfy, MD, PhD, FRCP, Chief Executive Officer, Spire Sciences Inc.; P.G. Conaghan, MB, BS, PhD, FRACP, FRCP, Professor of Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; M. Østergaard, MD, PhD, DMSc, Professor of Rheumatology, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet-Glostrup and Department of Clinical Medicine, University of Copenhagen.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.141010DOI Listing
December 2015

Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014.

J Rheumatol 2015 Nov 1;42(11):2198-203. Epub 2015 May 1.

From the Royal National Hospital for Rheumatic Diseases, Bath, UK; Toronto Western Hospital; Psoriatic Arthritis Program, University Health Network, Toronto Western Research Institute, Toronto, Ontario, Canada; St. Vincent's University Hospital, Dublin, Ireland; Quintiles; Duke University School of Medicine; Durham, North Carolina, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Chapel Allerton Hospital, Leeds, UK; Sorbonne Universités, Université Pierre et Marie Curie-Paris 6 (UPMC Univ Paris 6), Institut Pierre Louis d'Epidémiologie et de Santé Publique; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland; Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California, USA; University of Bath, Bath, UK; Swedish Medical Center, University of Washington, Seattle, Washington; Hospital of the University of Pennsylvania (HUP), Philadelphia, Pennsylvania, USA.W. Tillett, MB, ChB, BSc, MRCP, PhD, Research Fellow, Royal National Hospital for Rheumatic Diseases; L. Eder, MD, PhD, Postdoctoral Research Fellow, Toronto Western Hospital; M. de Wit, PhD, OMERACT Patient Research Partner, The Netherlands; D.D. Gladman, MD, FRCPC, Director, Psoriatic Arthritis Program, University Health Network, Senior Scientist, Toronto Western Research Institute; O. FitzGerald, MD, FRCPI, FRCP( UK), Consultant Rheumatologist and Newman Clinical Research Professor, St. Vincent's University Hospital; N. Goel, MD, OMERACT Patient Research Partner, Quintiles, and Duke University School of Medicine; W. Campbell, BEd, LLB, OMERACT Patient Research Partner; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 6, Institut Pierre Louis d'Epidémiologie et de Sant

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.141156DOI Listing
November 2015

Biologic Therapy for Psoriatic Arthritis.

Authors:
Philip J Mease

Rheum Dis Clin North Am 2015 Nov 7;41(4):723-38. Epub 2015 Sep 7.

Clinical Rheumatology Research, Swedish Medical Center, 601 Broadway, Seattle, WA 98122, USA; University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, WA 98195, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rdc.2015.07.010DOI Listing
November 2015

Is Chronic Pain a Disease in Its Own Right? Discussions from a Pre-OMERACT 2014 Workshop on Chronic Pain.

J Rheumatol 2015 Oct 1;42(10):1947-1953. Epub 2015 Jul 1.

From Cardiff University, Cardiff, UK; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA; Barry Chiropractic Clinic, Cardiff; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; SDG LLC, Cambridge, Massachusetts, USA; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Medicine Service, VA Medical Center, Birmingham; Department of Medicine at the School of Medicine, and Division of Epidemiology at the School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama; Department of Orthopedic Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota, USA; University Hospital Carl Gustav Carus, Dresden, Germany; Swedish Medical Center and University of Washington, Seattle, Washington; Division of Immunology/Rheumatology, Stanford University, Palo Alto, California, USA.

View Article

Download full-text PDF

Source
http://www.jrheum.org/content/42/10/1947.full.pdf
Web Search
http://www.jrheum.org/cgi/doi/10.3899/jrheum.141328
Publisher Site
http://dx.doi.org/10.3899/jrheum.141328DOI Listing
October 2015

Harmonizing Pain Outcome Measures: Results of the Pre-OMERACT Meeting on Partnerships for Consensus on Patient-important Pain Outcome Domains Between the Cochrane Musculoskeletal Group and OMERACT.

J Rheumatol 2015 Oct 1;42(10):1943-1946. Epub 2015 Aug 1.

From the Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA; Cardiff University, Cardiff, UK; Swedish Medical Center and University of Washington, Seattle, Washington, USA; SDG LLC, Cambridge, Massachusetts, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; University of Alabama at Birmingham, Birmingham, Alabama; Division of Immunology/Rheumatology, Stanford University, Palo Alto, California, USA; University Hospital Carl Gustav Carus, Dresden, Germany; Universite Pierre et Marie Curie and APHP, Department of Rheumatology, Pitie-Salpetriere Hospital, Paris, France; EMGO Institute for Health and Care Research, Department of Health Sciences, VU University, and Department of Epidemiology and Biostatistics, VU University Medical Center, VU Medical Center, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.141386DOI Listing
October 2015

Current State of Reporting Pain Outcomes in Cochrane Reviews of Chronic Musculoskeletal Pain Conditions and Considerations for an OMERACT Research Agenda.

J Rheumatol 2015 Oct 15;42(10):1934-1942. Epub 2015 Sep 15.

From the Ottawa Hospital Research Institute, Centre for Practice-Changing Research, Ottawa, Canada; School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa and Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, Canada; SDG LLC Cambridge, MA, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; University of Ottawa; Institute of Population Health, University of Ottawa, Ottawa; Institute for Work & Health, Toronto, Canada; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA; Department of Anesthesia, Department of Clinical Epidemiology and Biostatistics, and the Michael G. DeGroote Institute for Pain Research and Care, McMaster University, Hamilton, Canada; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; Quintiles, Inc., Division of Rheumatology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland; University Hospital Carl Gustav Carus, Dresden, Germany; University of Washington, Seattle, WA, USA; Department of Health Sciences (VU University) and Department of Epidemiology and Biostatistics (VU University Medical Centre) of the EMGO Institute for Health and Care Research, Amsterdam, The Netherlands; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA; Laboratory for Pain Research, University of Split School of Medicine, Split, Croatia; Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, AL, USA; Division Immunology/Rheumatology Stanford University School of Medicine, Palo Alto, CA, USA; Institute of Infection and Immunity, Cardiff University, Cardiff, UK; Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research, VU University Medical Center Amsterdam, Amsterdam, The Netherlands; University of Ottawa, Department of Medicine, Faculty of Medicine, Ottawa Hospital Research Institute; Clinical Epidemiology Program, University of Ottawa and School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa; Faculty of Medicine, Institute of Population Health, Ottawa, Canada.

View Article

Download full-text PDF

Source
https://fhs.mcmaster.ca/anesthesiaresearch/documents/JRheuma
Web Search
http://www.jrheum.org/content/42/10/1934.full.pdf
Web Search
http://www.jrheum.org/cgi/doi/10.3899/jrheum.141423
Publisher Site
http://dx.doi.org/10.3899/jrheum.141423DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649665PMC
October 2015

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.

N Engl J Med 2015 Oct;373(14):1329-39

From the Swedish Medical Center and the University of Washington - both in Seattle (P.J.M.); University of Glasgow, Glasgow (I.B.M.), and Guy's and St. Thomas' NHS Foundation Trust, London (B.K.) - both in the United Kingdom; University of California, San Diego, School of Medicine, San Diego (A.K.); Memorial University, St. John's, NL, Canada (P.R.); Leiden University Medical Center, Leiden (D.H.), and University of Amsterdam and Atrium Medical Center, Amsterdam (R.L.) - all in the Netherlands; University of Queensland, Brisbane, Australia (P.N.); Novartis Pharmaceuticals, East Hanover, NJ (L.P., J.Y.); and Novartis Pharma, Basel, Switzerland (H.B.R., S.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1412679DOI Listing
October 2015